Amgen says continues to see stabilization in Aranesp business by mid-year Says ESA business now represents "much smaller" proportion of overall sales. Says declines in ESA business more than offset by revenue gains in denosumab franchise in Q1.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.